Omnicell Investor Presentation Deck
Updated 2023 Guidance
Bookings¹
Total Revenues
Product Revenues
Service Revenues
Technical Services Revenues
Advanced Services Revenues
Non-GAAP EBITDA
Non-GAAP EPS
Q3-2023
Not Provided
$290-$300 Million
$185-$190 Million
$105-$110 Million
Not Provided
Not Provided
$31-$37 Million
$0.42-$0.52
TY-2023
$1.000-$1.100 Billion²
$1.160-$1.200 Billion
$740-$760 Million
$420-$440 Million
$215-$225 Million
$205-$215 Million
$130-$145 Million
$1.75-$2.00
We do not provide a reconciliation of forward-looking non-GAAP guidance to the comparable GAAP measures as these items are inherently uncertain and difficult to estimate and cannot be predicted without unreasonable effort.
1. We define bookings generally as: (i) the value of non-cancelable contracts for our connected devices, software products, and Advanced Services (although, for those Advanced Services contracts without a minimum commitment,
bookings only includes the amount of revenue that has been recognized once the services have been provided); and (ii) for our consumables, the value of orders placed through our Omnicell Storefront online platform or through written
or telephonic orders. We typically exclude technical services and other less significant items ancillary to our products and services, such as freight revenue from bookings.
2. For the full year 2023, the Company expects bookings to trend toward the lower end of the previously disclosed guidance range of $1.000 billion and $1.100 billion.
3. Represents estimated cumulative TAM over 10 years as of 5/31/2022 and includes the United States, UK&I, Germany, France, Spain, Kingdom of Saudi Arabia and Australia/New Zealand.
© 2023 Omnicell, Inc.
Long-Term Value
Creation Opportunities
Leadership position in the digital
transformation of healthcare with
$90 Billion+ TAM³
Emerging and scaling of Advanced
Services offerings
Platform adoption, expansion,
market share gains, and upgrade
cycles supporting growth
Strong balance sheet should enable
transformation to new business
model with expected higher gross
margins, EBITDA, and free cash flows
16View entire presentation